Date
27 January 2021
Access to Medicine and COVID-19
Jayasree refers to the positive, albeit limited, progress of the pharmaceutical companies to systematically pair candidate products with access plans, offering a few examples of best practice. Yet, she notes that a large portion of the products already available on the market remain unsupported by access plans.
She then compares the industry's response to the COVID-19 pandemic with the response to other infectious diseases identified as pandemic risks and concludes that the lessons learnt from this can guide the companies to become a catalyst for change in future.
Read the full article here.